FY2026 Earnings Forecast for Nevro Issued By William Blair

Nevro Corp. (NYSE:NVRO) – Stock analysts at William Blair issued their FY2026 earnings estimates for Nevro in a research report issued on Tuesday, November 12th. William Blair analyst B. Vazquez forecasts that the medical equipment provider will post earnings per share of ($2.46) for the year. The consensus estimate for Nevro’s current full-year earnings is ($2.60) per share.

Nevro (NYSE:NVRO) last released its earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.40. Nevro had a negative return on equity of 23.35% and a negative net margin of 16.54%. The company had revenue of $96.60 million during the quarter, compared to analysts’ expectations of $93.09 million. During the same quarter last year, the business posted ($0.65) EPS. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. cut shares of Nevro from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 7th. Wolfe Research raised shares of Nevro from an “underperform” rating to a “peer perform” rating in a research report on Thursday, August 8th. StockNews.com raised shares of Nevro from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Wells Fargo & Company downgraded shares of Nevro from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $13.00 to $5.50 in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $7.00 price objective on shares of Nevro in a report on Tuesday. Three analysts have rated the stock with a sell rating and twelve have given a hold rating to the company. According to data from MarketBeat, Nevro has an average rating of “Hold” and a consensus target price of $9.10.

Nevro Stock Performance

Shares of Nevro stock opened at $4.45 on Wednesday. The business has a fifty day simple moving average of $5.23 and a two-hundred day simple moving average of $7.44. The firm has a market capitalization of $165.91 million, a P/E ratio of -2.35 and a beta of 0.93. The company has a current ratio of 4.77, a quick ratio of 3.53 and a debt-to-equity ratio of 0.66. Nevro has a 12 month low of $4.38 and a 12 month high of $22.64.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NVRO. Armistice Capital LLC increased its position in shares of Nevro by 1.3% during the 2nd quarter. Armistice Capital LLC now owns 3,672,000 shares of the medical equipment provider’s stock valued at $30,918,000 after purchasing an additional 48,000 shares during the last quarter. Millennium Management LLC grew its position in Nevro by 21.4% during the second quarter. Millennium Management LLC now owns 956,542 shares of the medical equipment provider’s stock valued at $8,054,000 after buying an additional 168,573 shares during the period. Assenagon Asset Management S.A. increased its holdings in Nevro by 27.6% during the third quarter. Assenagon Asset Management S.A. now owns 929,348 shares of the medical equipment provider’s stock valued at $5,195,000 after buying an additional 200,885 shares during the last quarter. Renaissance Technologies LLC raised its position in Nevro by 5.0% in the second quarter. Renaissance Technologies LLC now owns 368,100 shares of the medical equipment provider’s stock worth $3,099,000 after acquiring an additional 17,600 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Nevro by 3.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 303,675 shares of the medical equipment provider’s stock worth $1,698,000 after acquiring an additional 11,369 shares during the last quarter. Institutional investors own 95.52% of the company’s stock.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.